Showing results (1-10 of 255) with videos related to
Sort By:
Pageof 26
Expert Opinion on Investigational Drugs|January 25, 2021
Angiogenesis in biliary tract cancer: targeting and therapeutic potentialMargherita Rimini, Andrea Casadei-GardiniCancers|January 22, 2021
Recent Research on Gastrointestinal CarcinomaGiulia Rovesti, Giorgia Marisi, Andrea Casadei-GardiniExpert Opinion on Investigational Drugs|March 11, 2022
Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical developmentMargherita Rimini, Nicole Liscia, Valentina Burgio, et al.Cancers|November 17, 2020
BRCA in Gastrointestinal Cancers: Current Treatments and Future PerspectivesEleonora Molinaro, Kalliopi Andrikou, Andrea Casadei-Gardini, et al.Expert Review of Anticancer Therapy|April 15, 2023
Understanding the causes of recurrent HCC after liver resection and radiofrequency ablationCarlo Bosi, Margherita Rimini, Andrea Casadei-Gardini, et al.Expert Review of Anticancer Therapy|January 8, 2020
Developments in predictive biomarkers for hepatocellular carcinoma therapyAndrea Casadei-Gardini, Giulia Orsi, Francesco Caputo, et al.Expert Review of Gastroenterology & Hepatology|March 23, 2026
The evolving role of futibatinib for advanced cholangiocarcinomaMara Persano, Andrea Casadei-Gardini, Silvia Camera, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 19, 2019
Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019Francesco Tovoli, Andrea Casadei-Gardini, Francesca Benevento, et al.Journal of Oncology|July 14, 2020
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line TreatmentGiandomenico Roviello, Andrea Casadei-Gardini, Stefania Nobili, et al.Expert Review of Clinical Pharmacology|May 13, 2020
Cabozantinib as a second-line treatment option in hepatocellular carcinomaAlberto D'Angelo, Navid Sobhani, Stefan Bagby, et al.Pageof 26